Press Release

Date: 07th August, 2026 BSE Limited, The National Stock Exchange of India Ltd, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, 5th Floor, Dalai Street, Bandra - Kurla Complex, Bandra (East), Mumbai - 400 001 Mumbai - 400051 Scrip Code: 530843 Symbol: CUPID Subject: Press Release – Q1 FY27 Financial Results Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir / Ma’am, With reference to the captioned subject, enclosed herewith the Press Release on Un-audited Financial Results of the Company for the quarter ended 30th June, 2026. This intimation is also being uploaded on the Company’s website at https://www.cupidlimited.com/ This is for your information and records. Thanking you. For Cupid Limited Hardik Chandra Company Secretary and Compliance Officer Encl: As above Press Release Q1 FY27 Financial Results Cupid Limited Delivers Strong Q1 FY27 Performance with 159% YoY Operating Income Growth, 194% YoY Net Profit Growth; FY27 Guidance Upgraded to ₹725 Cr – ₹750 Cr Revenue & ₹210 Cr - ₹225 Cr Net Profit Mumbai, 7th August 2026: Cupid Limited (“Cupid” or “the Company”), Bharat's rapidly growing consumer wellness and personal care company with a strong global healthcare franchise, announced its financial results for the quarter ended 30th June, 2026. Supported by continued business momentum and improved visibility across its healthcare and consumer businesses. Key Consolidated Financial Highlights Particulars (₹ in Cr) Q1 FY27 Q4 FY26 QoQ Q1 FY26 YoY Total Income 156.98 132.04 19% 64.75 142% Operating Income 154.72 119.96 29% 59.80 159% EBITDA 60.06 37.52 60% 16.47 265% EBITDA Margin 39% 31% 755 BPS 28% 1,127 BPS PBT 59.92 47.45 26% 19.55 206% Net Profit 44.15 36.26 22% 15.01 194% Strong Start To FY27 • Cupid commenced FY27 with strong momentum across its international B2B healthcare and domestic Consumer Healthcare & FMCG businesses, supported by healthy execution across key operating segments. • The Company's international B2B healthcare business continued to witness robust demand across PFSCM, WHO/UNFPA, institutional procurement programmes, government tenders and private export markets, providing strong order visibility and a healthy revenue pipeline. • Strong growth in operating income reflects the increasing contribution of the Company's core operating businesses, reinforcing the quality of earnings and the sustainability of its growth trajectory. • The Company expects sizeable orders across its IVD Kits portfolio from multiple State Governments in India, along with significant international opportunities following the receipt of CE certifications. Several opportunities are in the final stages of the award process, providing a strong near-term growth pipeline. • The Company has implemented a minimum 10% price increase across its export portfolio, supporting improved realizations and margin expansion. • A favourable USD/INR environment has supported export realizations, while prudent hedging of currency exposure relating to international investments helps mitigate foreign exchange risk. • Supported by a strong order book, expanding Consumer Healthcare & FMCG portfolio, healthy international B2B demand and expectations of robust performance during the second half of FY27, the Company has enhanced its FY27 guidance to ₹725 Cr - ₹750 Cr in revenue and ₹210 Cr - ₹ 225 Cr in Net Profit, reinforcing confidence in its long-term growth trajectory. Cupid Limited | Q1 FY27 Press Release BSE: 530843 | NSE: CUPID Cupid Limited Q1 FY27 Results • During FY26, the Company's Consumer Healthcare & FMCG portfolio contributed revenue of ₹121.61 crore, comprising domestic sales of male and female condoms, IVD kits, personal lubricants and newly launched FMCG products, including ₹84.26 crore from the newly launched FMCG portfolio. Strategic Investments Supporting Long-Term Value Creation • Strategic investments in Baazar Style Retail and GII Healthcare complement Cupid's Consumer Healthcare & FMCG and global healthcare businesses. • These strategic investments are expected to be value accretive over FY27 and beyond, supporting long-term shareholder value creation while strengthening Cupid's healthcare ecosystem, consumer platform and future growth opportunities. Palava Facility Progressing Towards Commissioning • The Palava manufacturing facility remains on schedule for commissioning during Q2 FY27, significantly enhancing Cupid's production capabilities and long-term manufacturing capacity. • The facility will support annual capacity of approximately 1.25 billion male condoms and 125 million female Palava, Maharashtra | ~170,000 sq. ft. condoms, including incremental capacity of approximately 770 million male condoms and 75 million female condoms. • Dual-polymer dipping technology, Natural Rubber Latex and Nitrile capabilities, dedicated production lines and interchangeable manufacturing lines will improve flexibility, supply reliability, tender participation and operating leverage. Continued Business Momentum Supports Revised Growth Outlook Financial Year Revenue Estimate Net Profit Estimate Original ₹600 Cr ₹180 Cr Updated ₹660 Cr+ ₹180 Cr+ Latest Revised ₹725 Cr - ₹750 Cr ₹210 Cr - ₹225 Cr (As On Date) • The Company has enhanced its FY27 guidance to ₹725 Cr - ₹750 Cr in revenue and ₹210 Cr - ₹225 Cr in Net Profit, supported by a strong order book, sustained momentum across its international B2B healthcare business and continued expansion of its Consumer Healthcare & FMCG portfolio. • The revised outlook reflects management's confidence in delivering strong performance through the remainder of FY27, supported by manufacturing expansion, healthy order visibility, operating leverage and multiple strategic initiatives to drive sustainable long-term growth. Cupid Limited | Q1 FY27 Press Release BSE: 530843 | NSE: CUPID Cupid Limited Q1 FY27 Results Management Commentary Commenting on the performance, Mr. Aditya Kumar Halwasiya, Chairman and Managing Director, Cupid Limited, said: “We have commenced FY27 with strong momentum across both our international B2B healthcare and Consumer Healthcare & FMCG businesses. Healthy execution during the quarter, improving order visibility and sustained demand across our core segments have strengthened our confidence in the Company's growth trajectory. Supported by a robust order book, healthy business momentum and strong visibility across our key operating segments, we have enhanced our FY27 guidance to ₹725 Cr - ₹750 Cr in revenue and ₹210 Cr - ₹225 Cr in Net Profit. Our Consumer Healthcare & FMCG business continues to gain meaningful traction and remains an important pillar of our long-term growth strategy. During the quarter, the business witnessed encouraging momentum across our diversified portfolio, supported by growing consumer acceptance and an expanding presence across modern trade, organised retail and pharmacy channels. We continue to strengthen our market penetration through a broad portfolio spanning domestic male and female condoms, IVD kits, personal lubricants and an expanding range of personal care and wellness products, positioning the business for sustainable long-term growth. Our international B2B healthcare business continues to demonstrate healthy momentum, supported by strong demand across PFSCM, WHO/UNFPA and other institutional procurement programmes, government tenders and private export markets. This diversified order pipeline provides strong revenue visibility and reinforces our leadership across global healthcare markets. The commissioning of our Palava manufacturing facility during Q2 FY27 will further strengthen our manufacturing flexibility, enhance supply capabilities and support future growth across both international healthcare and domestic Consumer Healthcare & FMCG businesses. We also expect our strategic investments to be value accretive for the Company over FY27 and beyond, further strengthening our long-term [Showing first 8,000 characters — download PDF for full document]